Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Galcanezumab in Japan
jRCT2080224674Phase 3Completed
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of galcanezumab in central nervous system conditions (CNSD). Started May 2019; status: completed.
02
Drugs
galcanezumab
03
Conditions
central nervous system conditions (CNSD)
Beyond the preview
Go deeper on jRCT2080224674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224674.